Small Molecules

29 Jun 2020 Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections
29 Jun 2020 Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure
29 Jun 2020 Cancer Prevention Pharmaceuticals Submits New Drug Application to the FDA for CPP-1X/sul for Treatment of Familial Adenomatous Polyposis
29 Jun 2020 TFF Pharmaceuticals Announces First Human Dosing With Tacrolimus Inhalation Powder and Topline Data for Voriconazole Inhalation Powder
28 Jun 2020 Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
28 Jun 2020 CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes
28 Jun 2020 Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT
26 Jun 2020 Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus (ABI-009, FYARRO™) for the Treatment of Advanced Malignant PEComa
26 Jun 2020 FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
26 Jun 2020 Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
26 Jun 2020 AiViva Biopharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
25 Jun 2020 Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study
25 Jun 2020 Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial
25 Jun 2020 Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session
24 Jun 2020 ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
24 Jun 2020 IM Therapeutics Announces First Patient Dosed in Phase 1 Study of Its Lead Drug IMT-002 for Type 1 Diabetes
24 Jun 2020 Sun Pharma Announces Pre-Clinical Data on GL0034, an Experimental NCE to Treat Type 2 Diabetes and Obesity
23 Jun 2020 Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
23 Jun 2020 Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program
23 Jun 2020 Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries
23 Jun 2020 ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA
23 Jun 2020 Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19
23 Jun 2020 Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
22 Jun 2020 RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting
22 Jun 2020 Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up